Follicle-stimulating hormone (FSH) is central to reproduction in mammals. It acts through a G-protein-coupled receptor on the surface of target cells to stimulate testicular and ovarian functions. We present here the 2.9-Å -resolution structure of a partially deglycosylated complex of human FSH bound to the extracellular hormone-binding domain of its receptor (FSHR HB ). The hormone is bound in a hand-clasp fashion to an elongated, curved receptor. The buried interface of the complex is large (2,600 Å 2 ) and has a high charge density. Our analysis suggests that all glycoprotein hormones bind to their receptors in this mode and that binding specificity is mediated by key interaction sites involving both the common a-and hormone-specific b-subunits. On binding, FSH undergoes a concerted conformational change that affects protruding loops implicated in receptor activation. The FSH-FSHR HB complexes form dimers in the crystal and at high concentrations in solution. Such dimers may participate in transmembrane signal transduction.
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FSH is secreted from the pituitary gland to regulate reproduction in mammals 1, 2 . In females, FSH targets a receptor (FSHR) expressed only on granulosa cells, and induces the maturation of ovarian follicles 1, 3 . The levels of both FSH and FSHR rise until the middle of oestrus, and then fall precipitously as luteinizing hormone (LH) triggers ovulation. In males, FSH stimulates sertoli cell proliferation in testes and supports spermatogenesis 1, 3 . FSH is used clinically to treat anovulatory women and infertile men, and we expect that a molecular understanding of the FSH interaction with FSHR may assist in the design of contraceptive antagonists and alternative agonists.
FSH is a member of the glycoprotein hormone family, which also includes LH, chorionic gonadotropin (CG) and thyroidstimulating hormone (TSH) 4 . These glycoprotein hormones are disulphide-rich heterodimers consisting of non-covalently associated a-and b-subunits 4 . In a given species, they share a common a-chain but derive functional specificity from different b-chains 4 . Crystal structures of human CG (hCG) 5, 6 and FSH 7 both reveal elongated molecules with similar folds for the a-and b-chains, and a cysteine-knot motif in the central core of each subunit. The interactions between the glycoprotein hormones and their corresponding receptors are highly selective, with very few cases of cross activity 3 . The glycoprotein hormones act through specific G-proteincoupled receptors (GPCRs) on target cell surfaces 1, 8, 9 . FSH and TSH bind to FSHR and TSHR, respectively; LH and CG both bind to the same receptor, LHR. These receptors belong to a subfamily of GPCRs called leucine-rich-repeat-containing GPCRs (LGRs), which are characterized by an extracellular domain with multiple leucine-rich repeats (LRRs) and a rhodopsin-like domain of seven transmembrane (7TM) helices 10 . Unlike most other GPCR proteins, which have relatively short extracellular segments and bind small molecule ligands, the LGRs have large ectodomains and bind protein ligands including glycoprotein hormones and relaxin 10 . Ligand binding and receptor activation appear to be distinct activities of glycoprotein hormone receptors. The extracellular domains of glycoprotein hormone receptors are responsible for the specificity and high affinity of ligand binding (typically at subnanomolar dissociation constant (K d ) values 2, 8 ), whereas the transmembrane domains are responsible for receptor activation and signal transduction through G proteins 1, 8, 9 . Hormone binding to the ectodomain of a glycoprotein hormone receptor somehow prompts changes in the 7TM domain that propagate across the plasma membrane to elicit guanine nucleotide exchange in a heterotrimeric G s protein. Activation of adenylyl cyclase for the production of cAMP ensues, thereby initiating a signalling cascade that leads to steroid synthesis 1, 8, 9 . In an effort to understand ligand binding and receptor stimulation in this signalling pathway, we have determined the crystal structure of human FSH bound to the hormone-binding domain of its receptor. Our finding of receptor-mediated dimers in the crystal prompted us to study dimerization in solution and to contemplate its role in signal transduction on the membrane.
Assembly of the FSH-FSHR HB complex
Human FSH and a truncated ectodomain of human FSHR were cosecreted as a stable complex from insect cells using the baculovirus expression system. The a-and b-subunits of the heterodimeric FSH were joined into a single chain with a Gly/Ser-rich linker from the carboxy terminus of the b-subunit to the amino terminus of the asubunit; similar FSH and CG constructs, but with different linkers, have been shown to retain a wild-type level of function [11] [12] [13] . All glycoprotein hormone receptors comprise a series of LRRs flanked at each end by cysteine clusters. Refolding experiments of recombinant LHR indicate that the N-terminal cysteine cluster is required for proper folding (data not shown). A truncated FSHR consisting of the N-terminal cysteine cluster and the LRRs forms a stable complex with FSH, indicating that the C-terminal cysteine-rich region of the ectodomain is not required for hormone binding. We therefore define the N-terminal cysteine cluster together with the LRRs as the hormone-binding domain of the receptor (FSHR HB ).
Structure determination
Co-secreted FSH and FSHR HB form a 1:1 complex as demonstrated by its retention time upon gel filtration chromatography (data not shown). The fully glycosylated FSH-FSHR HB complex could be crystallized in several different forms, the best of which only diffracted to 9 Å spacings. Partial deglycosylation using a combination of endoglycosidases F2 and F3 yielded a new crystal form, which diffracted to 2.9 Å spacings. The crystals are of space group C2, with two complexes in the asymmetric unit. The complex structure was determined by molecular replacement. The positions of the two hormone molecules were located using the known structure of human FSH 7 as the search model. Partial phases obtained from the molecular replacement solution were improved by two-fold molecular averaging to yield electron density for the bound receptor. A complete model of the complex was developed iteratively and refined ultimately at 2.9 Å resolution to an R-value of 21.9% (R free ¼ 25.9%).
Receptor structure consisting of irregular repeats FSHR HB is formed from its LRR winding into the shape of a slightly curved tube (Fig. 1a, b ; see also Supplementary Fig. S1 ). As predicted from sequence considerations 14 and as found in other LRR structures 15 , its concave inner surface is an untwisted, noninclined b-sheet and its tubular hydrophobic core is filled by LRR namesake leucines and other large hydrophobic residues. The repeats themselves are highly irregular in length and conformation, and particularly so in the outer surface returns. Regular structure in the convex outer surface is limited to seven short b-strands in three sheets (Fig. 1c) . Unexpectedly, the N-terminal flanking sequence (residues contains the first of the LRR repeats. This segment is further integrated into the structure by an antiparallel b-strand added before the inner b-sheet and by two disulphide bridges (Cys 18-Cys 25 and Cys 23-Cys 32) ( Fig. 1a ; see also Supplementary  Fig. S2 ).
Unlike other known LRR structures, the curvature of FSHR HB is steeply graded; the C-terminal portion (repeats 7-10) has the signature horseshoe-like curvature of LRR proteins whereas the N-terminal portion of the inner b-sheet (repeats 1-7) is nearly flat. Apart from repeat 1, the overall fold of FSHR HB is likely to be conserved in LHR and TSHR, and across mammalian species, because Leu/Ile/Phe residues in the hydrophobic core of FSHR HB are conserved at equivalent positions in the sequences from LHR and TSHR (Fig. 2c) and almost all repeat irregularities are also conserved. We are describing FSHR HB structural details and comparisons to other LRR proteins elsewhere.
A hand-clasp binding mode
The structure of the FSH-FSHR HB complex shows FSH bound into the concave face of the curved receptor domain in a manner that resembles a hand clasp (Figs 1a, b and 2a), roughly as in our prediction 14 . The long axis of FSH is perpendicular to the FSHR HB tube and aligned with receptor b-strands. All ten parallel b-strands and the loops just C-terminal to the b-sheet are in contact with FSH ( Fig. 3a; see also Supplementary Fig. S1 ). The receptor wraps around the middle section of the hormone molecule, interacting with C-terminal segments of both FSH-a and FSH-b as well as the aL2 and bL2 loops. The hormone orientation is such that loops bL1 and bL3 extend out from the C-terminal tips of the receptor inner sheet, whereas loops aL1 and aL3 protrude away from the base.
The footprints of hormone and receptor onto their partner surfaces ( Fig. 2a ; see also Supplementary Fig. S1 ) demonstrate the substantial involvement of both FSH subunits in the interaction with FSHR HB . A total of 2,600 Å 2 of solvent-accessible surface area from the isolated components is buried into the interface between FSH and FSHR HB . Most of this interface involves the packing of two rather flat surfaces: one formed by the seven N-terminal parallel b-strands of FSHR HB is matched with one from the C-terminal segment of FSH-a and the C-terminal 'seat-belt' segment of FSH-b. The rest comes from the aL2 loop with its helical segment clamping over the edge of FSHR HB at the b-strand tips of LRRs 2-6, and from the bL2 loop fitting against the curved C-terminal repeats 8-10. A significant consequence of this geometry is that a swathe of the most deeply buried interfacial receptor residues ( Fig. 2c ; see also Supplementary Fig. S3 ) lies across the C-terminal end of the parallel b-sheet (Fig. 3a) . Half of these FSHR HB residues (L55, N79, K104, N129, Q152, D153 and K179) are buried by contacts with both FSH-a and FSH-b (Fig. 2a, magenta) .
The interface between hormone and receptor is bare of carbohydrate groups. Sufficient density was found to model carbohydrate residues (1-3) at all four potential glycosylation sites on the hormone (FSH-a N52 and N78; FSH-b N7 and N24) and at the one verified glycosylation site on our receptor construct (N191) 16 . All of these sites are remote from the interface (Fig. 1a, b) . Even the closest carbohydrate moiety, at FSH-a N52, faces away from the receptor interface. Glycosylation at FSH-a N52 has been implicated in signalling but not in binding 2 . Natural mutations located at or close to the conserved glycosylation site of FSHR (N191I, A189V) have been shown to cause inactivation of the receptor 2 , possibly by affecting the proper folding of FSHR 16 .
Charge complementarity in a universal binding interface
Several lines of evidence suggest that the mode of binding seen here between FSH and FSHR HB probably also pertains to other mammalian glycoprotein hormones and their receptors. First, highly similar structures for human FSH 7 and CG 5, 6 , and highly conserved sequences for LH and TSH, including identical a-chains within a species, point to a common ligand structure in the complex. Second, for reasons noted above, we expect the structure of the hormonebinding domain to be essentially the same in all glycoprotein hormone receptors. Third, previous studies on the different systems 1, 8, 9 implicate the very structural elements found in our FSH- FSHR HB complex to be involved in the interaction: namely the LRRs of the receptor and the C-terminal segments of the hormone subunits. Last, residues in the receptor homologues at positions where FSHR HB contacts FSH-a are consistent with a common mode of binding (Fig. 2c) . Many of these residues are conserved, and several are charged groups interacting with complementary groups on the hormone. The interface between FSH and FSHR HB has an exceptionally high buried-charge density in comparison to other protein complexes (1.13 charges per nm 2 ; Q.F. & W.A.H., unpublished data). The electrostatic potential surfaces of the hormone and receptor in the interface are predominately positive and negative, respectively, although less uniformly than in the putative CG-LHR complex 14 . The electropositive and electronegative patches in the interface reflect direct interactions between residues with complementary charges (Fig. 2b) , many of which are conserved in the homologues. Two invariant acidic residues (D150 and D153 in FSHR) make salt bridges with basic residues from FSH-a (K91 and K51). In addition, D81 from FSHR HB (also Asp in LHR) forms charge-mediated interactions with R42 and K45 of the aL2 loop of FSH. These findings are consistent with previous studies. Charge reversal mutagenesis of E132 and D135 individually to Lys in LHR (residues corresponding to D150 and D153 in FSHR) abolished hCG binding 17 ; mutation of FSH-a residues K51 (ref. 18) or K91 (ref. 19 ) to Ala caused the loss of receptor-binding activity; and inhibition of hormone binding using synthetic peptides indicated that the aL2 regions of both human CG and TSH are involved in receptor binding 20, 21 .
Specificity jointly mediated by hormone a-and b-subunits
Having common a-chains within a species, glycoprotein hormones must be distinguished by their b-chains. Important discriminating determinants of receptor binding have been localized to b-chain C-terminal segments [22] [23] [24] [25] that correspond to a unique seat-belt feature of the hormone structures [5] [6] [7] . The C-terminal end of the b-subunit embraces the a-subunit and fastens into place via a disulphide tether back to the body of the b-subunit [5] [6] [7] . The seat-belt segment of FSH-b (89-105, Fig. 2d ) is indeed at the interface, but it is sandwiched between the aL2 loop and C-terminal segment of FSH-a ( Fig. 3a; see also Supplementary Fig. S4 ). Specificity pockets for residues of FSHR HB form through coordination between discriminating b-chain seat-belt residues and common a-chain residues. The only other part of FSH-b at the interface is the tip of loop bL2 (40) (41) (42) (43) (44) (45) .
We have analysed interfacial contacts for potential determinants of specificity (Supplementary Table S1 and Fig. S5 ). Five substantially buried (,40% exposed) FSHR HB residues (L55, E76, R101, K179 and I222; Fig. 2c ) both vary among human receptors and make contact with FSH residues that vary among the counterpart hormones. Sequence variations indicate that hormone seat-belt interactions with receptor residues at positions 55 and 179 determine the specificity between FSH and TSH versus LH/CG, whereas residues at positions 76 and 101 distinguish between FSH and TSH. The interaction between position I222 and bL2 does not appear to be strongly discriminating. Other variable residues that are substantially buried in FSHR HB (Q79, E103, K104, Q152 and D196; Fig. 2c ) are covered in part by FSH-b but are not in direct contact with it; however, they could be selective in homologous complexes. Although collective interfaces must contribute to specificity, three sites appear to predominate. These focus on receptor residues corresponding to L55, K179 and the combination of E76 and R101 in FSHR. The molecular surface of FSH provides a shallow pocket for the side chain of L55, which forms hydrophobic interactions with L99 and Y103 of FSH-b and with the aliphatic part of R42 from FSH-a (Fig. 3b) . Substitution of L55 in FSHR with the Tyr residue found in LHR resulted in marked loss of function and hormone binding for the mutant receptor 26 , and it is clear from the structure that steric hindrance would preclude accommodation of the larger Tyr residue in the shallow pocket for L55. The residues in LH or CG (D105 and T109) that correspond to L99 and Y103 in FSH-b are smaller and could potentially form polar interactions or hydrogen bonds with the Tyr residue found in LHR. Conversely, these polar groups in LH/CG would not be complementary to the hydrophobic L55 of FSHR, and indeed FSH binding to FSHR is impaired when residues 95-100 of FSH-b (TVRGLG) are replaced with residues 101-106 of LH-b (GGPKDH) 24 . A channel on the molecular surface of FSH hosts the side chain of FSHR K179 (Fig. 3b) . The sides of this channel come from K51 and K91 of FSH-a, which make the universal salt bridges discussed above, and its top is capped by S89 and D90 of FSH-b, which form three hydrogen bonds with K179 of FSHR. S89 is substituted with R95 in the b-subunits of CG/LH (Fig. 2d) . Adverse interactions of this Arg residue with K179 would be expected to destabilize a potential complex between CG/LH and FSHR. Thus, the structure affords an explanation for extensive mutagenesis studies showing that K179 of FSHR functions as a negative determinant to prevent the binding of CG/LH to FSHR 26, 27 ; for example, mutation of K179 to the Gly residue found in LHR gave the mutant FSHR a gain of sensitivity towards hCG 26 . Moreover, FSH acquires LHR binding activity when residues 88-91 of FSH-b (DSDS) are replaced with their LH-b counterparts (94-97; RRST) 24 . A common feature of the specificity pockets for L55 and K179 is the involvement of residues from both the a-and b-chains of FSH, combining stereochemical orientation with specific interactions to mediate selectivity. The third site of selectivity involves the a-chain less directly. Structurally adjacent FSHR HB residues E76 and R101 ( Supplementary Fig. S5 ) interact primarily with R97 and V96 (respectively) from FSH-b, although FSH-a segments contribute to solvent exclusion. Charged side chains do not make hydrogenbonding contacts here, but repulsion expected from FSHR residues E76 and R101 interacting with the TSH-b Glu and His counterparts of R97 and V96 might explain FSH versus TSH selectivity. Although TSH chimaeras substituted with the FSH-b seat-belt segments failed to elicit follitropic activity, their reduced thyrotropic responses are compatible with our predictions 25 . The lengthened bL2 loop of TSH may also participate in selectivity.
Receptor-induced conformational changes in hormone
Although the free and receptor-bound structures of FSH are generally similar, the hormone conformation is substantially changed and appreciably rigidified in the complex (Fig. 4) . Free FSH is evidently quite flexible (Ca root-mean-squared deviation (r.m.s.d.) of 1.85 Å between copies 7 ), and this is especially true at termini and for the aL1, aL3 and bL2 loops at one end. The C terminus of FSH-a and these basal loops are the elements subject to receptor-induced conformational changes, which move them into a fixed conformation (Ca r.m.s.d. of 0.71 Å between copies) distinct from any in the free state (Ca r.m.s.d. of 1.5-2.9 Å overall; 2.6-6.3 Å for the C terminus of FSH-a and the loops a13-26, a66-78, a88-92 and b36-47). The conformation of free CG 5, 6 is also distinct from bound FSH.
The most marked change occurs at the C terminus of FSH-a where the terminal segment (88-92) is rotated almost 1808 to place its end more than 20 Å away from the free-state position. This segment is buried into the receptor interface where it is fully ordered, whereas the last two residues are disordered in free FSH 7 , as are the last three in hCG 5, 6 . Extensive interactions with the receptor include five direct hydrogen bonds, water-mediated contacts, and hydrophobic interactions (Fig. 3c) . Many of these contacts involve residues that are conserved among glycoprotein hormone receptors, consistent with a universal mode of binding.
A key feature of involvement of the FSH-a C terminus in the interface is an aromatic ring-stacking interaction between Y88 of FSH-a (Y127 in human LHR and F130 in TSHR) and Y124 of the receptor. Y88 also forms a hydrogen bond with E99 of FSHR. Altogether, 106 Å 2 of solvent-accessible surface area from Y88 on FSH-a is buried into the interface. Y88 is the first residue to diverge significantly from the free-state conformation, and its importance in the receptor interaction is demonstrated by experiments where deletion of the terminal residues 88-92 of hCG-a essentially eliminates receptor binding, whereas deletion of just the last four (89-92) retains binding albeit with reduced potency 28 . Alanine mutagenesis at the C terminus of FSH-a showed that six contiguous residues including Y88 contribute to the FSH-FSHR interaction 19 . The basal loops are locked into their receptor-bound state, presumably one favourable for GPCR activation, through interactions that begin with FSH bL2 contacts in the complex. Multiple free-state conformations of bL2 would conflict with the receptor in the complex and with the receptor-bound conformation of the FSH-a C terminus. Instead, bL2 adopts a new and fixed conformation by interacting positively with the three C-terminal LRRs of FSHR HB (Supplementary Table S1 and Fig. S4 ). Then, it seems that contacts of bL2 with its aL3 neighbour move that loop elastically by up to 7.0 Å . In turn, contacts of aL3 with aL1 press the elastic deformation into aL1 to define the final bound-state conformation.
Dimerization of the FSH-FSHR HB complex
The two independent complexes of FSH-FSHR HB in the crystal interact to constitute a dimer. A quasi-two-fold axis of rotational symmetry (rotation x ¼ 175.28, screw translation t x ¼ 21.2 Å ) relates the two protomers, passing between receptor molecules approximately perpendicular to the tube axes, such that the tips of aL1 and aL3 from the hormone are coplanar (Fig. 5a ). The dimer interface involves the three-stranded b-sheet (LRRs 2-4) on the outer surface of FSHR HB (Fig. 5b) . Y110 (Fig. 2c ) contributes prominently in a largely hydrophobic interaction, mediating 21 out of 24 direct carbon-carbon contacts. Because Y110 is completely conserved (Fig. 2c) , the homologous receptors may form dimers in a similar manner. The solvent-accessible surface area buried at the dimeric interface is relatively small (940 Å 2 total from both nonhydrated protomers), which suggests a weak association.
Dimers of the FSH-FSHR HB complex were detected in solution by chemical crosslinking, analytical centrifugation and light scattering. Crosslinking of FSH-FSHR HB with equal or less than equal molar ratios of glutaraldehyde produced dimer bands on SDS and native gels in a concentration-dependent manner. Quantification of dimer formation as a function of protein concentration could be fitted with a K d of 453^140 mM (Fig. 5c) . Sedimentation equilibrium experiments indicated that the FSH-FSHR HB complex exists in a monomer-dimer equilibrium (Fig. 5d) with a K d of 388^120 mM. Dynamic light-scattering measurements for FSH-FSHR HB showed that the apparent hydrodynamic radius increased 25% over the concentration range of 15-390 mM (Fig. 5e) , well beyond the concentration dependence found for non-associating proteins.
Implications for receptor activation
We expect the picture of ligand binding provided by the FSH-FSHR HB complex to apply to all glycoprotein hormone systems, as discussed above. Moreover, glycoprotein hormone receptors have 7TM portions that are very similar, both to one another (,70% sequence identity) and to other rhodopsin-family GPCRs, and when activated they can directly stimulate the same G s protein used by other GPCRs.Thus, we anticipate a mechanism for receptor activation that is essentially the same for FSHR, LHR and TSHR, and one that has elements in common with other GPCRs 29 . Now that we have structures in hand for an ectodomain complex with an activating ligand and for rhodopsin 30 as an inactive-state model of the 7TM domain, we are in a position to contemplate receptor activation in this system. To do this, we must first understand how the FSH-FSHR HB complex is oriented relative to the 7TM portion. Mapping experiments show that hormone epitopes on both the a-tip (aL1, aL3) and b-tip (bL1, bL3) are antibody accessible in hCG-porcine LHR (pLHR) ectodomain complexes but accessibility to the a-tip is occluded in complexes with fulllength pLHR 31 . Thus, we believe that the complex is oriented as in Figs 1, 4 and 5 relative to a cell surface below it: that is, with a-tips membrane-proximal and the receptor dyad approximately normal to the surface.
At least three models have been suggested for the activation of glycoprotein hormone receptors 8 . One invokes hormone-induced conformational changes in the ectodomain that directly activate the 7TM domain 32 ; a second features ectodomain constraints on activity that are released by hormone binding or by certain mutations 33 ; and a third proposes that it is the hormone when bound to the ectodomain that directly activates the 7TM domain 14, 31, 32 . Elements of each might be involved. Although aspects of hormone binding and receptor activation are separable, these models imply a necessary thermodynamic linkage.
We do not yet know the structure of free FSHR HB , but based on other LRR structures 15 it seems unlikely that any substantial changes in this domain accompany hormone binding (model 1). Certainly nothing of the kind found in the dimeric ectodomains of metabotropic glutamate receptors 34 is feasible here. Moreover, the finding that LHR/FSHR chimaeras with swapped extracellular domains respond fully in accord with hormone-binding selectivity 32 implies that membrane-proximal surfaces of the hormone-binding domain, which are quite variable, are not involved in activation.
The model of hormone-released inhibition (model 2) derives from observations of ectodomain mutations that confer hormoneindependent, constitutive activity to the receptor 33 . These mutations, at receptor counterparts of S273 just beyond the end of FSHR HB , are in a conserved segment in the linker connecting the LRRs to the 7TM domain. Apart from conservation at each end and at six cysteine positions, which are thought to create a condensed structure by disulphide bridging, these linkers are highly variable among receptors in sequence and length (87-137 residues). Whether S273 mutations truly release inhibition or activate positively is unclear because receptors lacking ectodomains are inactive 8 or not fully active 33 . Semantics aside, involvement of the linker region in activation is apparent both from these mutations and from the requirement for tyrosine sulphation at a site towards the membrane end of the linker 35 . The aL1/aL3 tips in the complex protrude towards a space where they might interact with the linker structure in normal, hormone-directed signalling.
The FSH-FSHR HB structure is fully compatible with direct interactions between the a-tips of the hormone in its receptorbound conformation and the 7TM domain and linker elements (model 3). The bL2 loop would seem to be hidden from direct contact, but its integrity would be essential to generate the bound conformation of aL1 and aL3 (Fig. 4) . Such activation might be mediated either by contacts with 7TM loops or, plausibly, by insinuation into the 7TM barrel after displacement of the second extracellular loop (EL2) 30 . Several experiments are consistent with this model, including the chimaeric exchanges 32 , antibody occlusion 31 , EL2-peptide inhibition of signalling and a-tip antibody access 31 , and signal-enhancing aL1 mutations 36 . Moreover, the remoteness of the carbohydrate at FSH-a N52 from conceivable activation sites is consistent with results from disulphide-stabilized hCG showing no effect on activity as a result of mutational deglycosylation at this site 37 . On the other hand, the structure is incompatible with experiments implicating the C terminus of the a-subunit in receptor activation 38 . Our observation of dimerization by the FSH-FSHR HB complex suggests that such dimerization may also have a role in glycoprotein hormone receptor function (Fig. 5f) . Indeed, dimerization is increasingly found to be important for signal transduction by GPCRs 39 . Although the dimeric interaction seen for soluble FSH-FSHR HB is quite weak (K d ,400 mM), this affinity is expected to be enhanced substantially when the receptors are anchored in the membrane 40 . Dimerization of hormone-receptor complexes is consistent with the co-expression of mutant receptor defective in hormone binding with others defective in signal transduction, whereby ligand-induced cAMP production is reconstituted 41, 42 , and also with direct measures of self-association through coimmunoprecipitation of differentially tagged receptors 43 or by fluorescence-resonance energy transfer experiments 44 . Puzzles do remain, however, as receptor C termini in the dimeric complex are separated by a distance (74.3 Å ) that, depending on linker flexibility, may be too great to accommodate contacts between associated 7TM domains (Fig. 5f) . A
Methods Protein expression and purification
We made a pFastBac Dual plasmid (Invitrogen) to encode both human FSH and human FSHR HB under control of separate promoters for introduction into a baculovirus vector. The hormone construct comprises the signal peptide and entire mature sequence of FSH-b (residues 1-111) followed by a 15-residue linker (GGGSGGGSGGGSGGG) and the mature sequence of FSH-a (residues 1-92). The receptor construct comprises the native signal sequence followed by the FSHR HB ectodomain (residues 1-268) and a Flag tag to facilitate purification. Hi5 cells infected with this recombinant baculovirus secreted the FSH-FSHR HB complex, which we purified from the cell supernatant by affinity chromatography (anti-Flag antibody M2) and size exclusion chromatography (Superdex200). The yield of purified FSH-FSHR HB was about 0.1 mg per litre of insect cell culture. We partially deglycosylated the complex using endoglycosidases F2 and F3, and purified the product by ion exchange chromatography (MonoQ).
Crystallization and data collection
Fully glycosylated FSH-FSHR HB were crystallized from tert-butanol into large polyhedra. These crystals are in space group R32 (a ¼ 227.2 Å , a ¼ 80.38) with an estimated five to ten complexes per asymmetric unit, but they diffract only to 9 Å spacings (NSLS beamline X4A 
Structure determination and refinement
We used molecular replacement and molecular averaging to solve the structure. A two-fold non-crystallographic symmetry (NCS) axis was identified from the self-rotation function, and the known structure of FSH 7 was used as the search model in Amore 46 to locate both FSH molecules in the asymmetric unit. After rigid-body refinement against all data (25-2.9 Å ), phases from this model were improved by two-fold NCS averaging in DM 47 . The resulting electron-density map revealed a b-sheet in the receptor region as predicted for the LRR motif of FSHR HB . We developed a complete atomic model of the complex through a succession of manual fittings and iterative averaging. Optimal NCS restraints were determined from an R free analysis (Q. , one mannose and ten N-acetylglucosamine residues, 50 water molecules, and three sulphate ions. Continuous density was observed for carbohydrate moieties at all N-linked glycosylation sites on one FSH-FSHR HB complex (aN52, aN78, bN7 and bN24 of FSH; N191 of FSHR HB ) and three sites on the other (aN78 0 and bN24 0 of FSH 0 ; N191 0 of FSHR HB 0 ). There was no density for residues of the Flag-tagged peptide and the FSH-b-FSH-a linker, presumably due to disordering. A Ramachandran analysis (http://kinemage.biochem.duke.edu) places 92.1% of all residues in favoured regions and 0.9% in outlier regions.
Chemical crosslinking
We carried out reactions of the FSH-FSHR HB complex at concentrations up to 360 mM with fixed molar ratios of glutaraldehyde that were sufficiently low to prevent adventitious crosslinking at higher protein concentrations (30 lysines per complex). A concentrationdependent dimer band on native gels was quantified by densitometry. The dimer-band density (D) from this crosslinked subpopulation is proportional to the equilibrium dimer fraction, D ¼ Sy, where S is a scaling factor, and the dimer fraction (y) depends on the total protein concentration (C T ) and K d according to
A least-squares fitting of the D(C T ) data gave estimates of S and K d .
Analytical ultracentrifugation
We carried out sedimentation equilibrium experiments using absorption optics in a Beckman XL-I analytical centrifuge. Purified fully glycosylated FSH-FSHR HB was analysed at three concentrations (0.33, 0.66 and 1.05 mg ml
21
) and three rotor speeds (7,000, 9,000 and 12,000 r.p.m.). Data were analysed with WinNONLIN 50 , floating the monomer mass to determine the extent of glycosylation. The FSH-FSHR HB mass was found to be 78 kDa, implying 32% carbohydrate mass.
Dynamic light scattering
We measured hydrodynamic radii of FSH-FSHR HB using a DynaPro molecular sizing instrument (Protein Solutions).
See supplementary information for details of the Methods. where kI h l is the average intensity over symmetry equivalent. † Rwork ¼ SkFoj 2 jFck=SjFoj: R free is equivalent to R work , but calculated for a randomly chosen 5% of reflections, which were omitted from the refinement process.
